Teleflex wins FDA nod for next-gen peripheral snares, launches in US
Teleflex (NYSE:TFX) said today it won FDA 510(k) clearance for its Expro Elite and Sympro Elite peripheral interventional snares and that it launched the devices in the US. Both newly cleared snares are next-generation versions of 0.035″ interventional snares launched in the US in 2008 by Vascular Solutions, which is now a wholly-owned subsidiary of Teleflex. The Expro Elite snare is designed to use a helical loop for all-direction capturing, and the Sympro Elite snare is designed to use a 90-degree loop which remains coaxial to the vessel, the Wayne, Penn.-based company said. Both devices are designed for use in the cardiovascular system and hollow viscus to retrieve or manipulate objects using minimally invasive surgical procedures. “We are excited to introduce to the market our enhanced versions of the Expro Elite and Sympro Elite Interventional Snares, which build on nearly a decade of reliable performance in the cath lab. Both devices feature greatly enhanced pull force for superior handling in challenging procedures. Both snare products feature a durable nitinol construction that retains its shape and adds strength, a radiopaque gold-plated tungsten coil and tip for enhanced visibility, 1:1 torque response for controlled positioning and better access to distal targets, and a unique locking handle that facilitates secure capture,” prez &interventional division GM Stewart Strong said in a press release. Last December, Teleflex said it inked...
Publication date: Available online 20 October 2018Source: Urology Case ReportsAuthor(s): Y. Ayari
Publication date: Available online 20 October 2018Source: Urology Case ReportsAuthor(s): Vincent Khor, LIE Kwok Ying
In this report, we looked at opioid medication use following discharge after radical prostatectomy. We found that 77% of opioid pain medication prescribed was unused, with 84% of patients using less than half of their prescription. Prescribing more opioids was associated with greater use; only 9% of patients appropriately disposed of leftover medication.
Authors: Voulgaris A, Nena E, Steiropoulos P PMID: 30338831 [PubMed - in process]
Authors: Fisichella R, Benfatto S, Berretta S PMID: 30338830 [PubMed - in process]
Authors: Pintaudi B, Di Vieste G, Corrado F, Lucisano G, Giunta L, D'Anna R, Di Benedetto A Abstract OBJECTIVE: Myo-inositol supplementation prevents gestational diabetes (GDM) in women at risk and reduces insulin resistance in women with GDM. No data are available about its effect on glucose variability. The aim of this study was to evaluate the effects of a supplementation of myo-inositol on glucose variability in women with GDM. PATIENTS AND METHODS: Myo-inositol effect on glucose variability was studied in a pilot case-control study involving 12 consecutive pregnant women (median age 34 years, 25.0% insulin...
CONCLUSIONS: MiR-124 down-regulation was associated with renal cancer cell OS-RC-2 invasion enhancement. Over-expression of miR-124 attenuated OS-RC-2 cell invasion by down-regulating STAT3 and MMP-9. PMID: 30338828 [PubMed - in process]
CONCLUSIONS: We found that the majority of human milk samples included beta-lactams or quinolones, even though the mothers did not receive these antibiotics during pregnancy and lactation. Antibiotic residues in human milk may affect early maintenance of the intestinal microbiota. Previous studies have shown that antimicrobials in food might increase the risks of allergies and could lead to the development of antibiotic-resistant bacterial strains. Effective policies on food safety and appropriate antibiotic use during pregnancy and lactation are needed. PMID: 30338827 [PubMed - in process]
CONCLUSIONS: Cyclosporine protects HK-2 cells from inflammatory injury via regulating mTOR pathway. PMID: 30338826 [PubMed - in process]
Authors: Golino M, Spera FR, Manfredonia L, De Vita A, Di Franco A, Lamendola P, Villano A, Melita V, Mencarelli E, Lanza GA, Crea F Abstract OBJECTIVE: About one-third of patients undergoing percutaneous coronary interventions (PCIs) for flow-limiting coronary stenosis continue to develop signs of myocardial ischemia (MI) during exercise stress test [EST], despite successful coronary revascularization. Coronary microvascular dysfunction is a likely major cause of the persistence of EST-induced MI in these patients. PATIENTS AND METHODS: We studied 15 patients (14 men, age 67±5 years) fulfilling the foll...